Sponsor safety letters and CIOMS/MedWatch reports
Process sponsor safety communications including IND safety reports, CIOMS forms, and MedWatch reports through a structured workflow that ensures investigator review, team notification, and appropriate IRB reporting.
The receiving end of the pharmacovigilance system
In a Phase III trial with 200 sites spread across 30 countries, each investigating site may receive between 50 and 200 individual IND safety reports over the course of the study. Some sites in long-running cardiovascular or oncology trials report receiving significantly more. Each of those reports describes a serious adverse event that occurred at another site -- an event the sponsor has determined to be both unexpected and suspected to be drug-related. Each report requires investigator review. Each requires acknowledgment. Each must be filed. And some -- the ones that change what you know about the drug's safety profile -- require action.